What happened, in summary

A 55-year-old woman had a 1.1 cm mass detected at the 11 o’clock position of the left breast. Biopsy showed grade II ductal carcinoma in situ with micropapillary and cribriform features, and the lesion was ER-positive.

She underwent lumpectomy with placement of a BioZorb marker, followed by postoperative radiation. Mammographic surveillance was performed every six months.

At the three-year examination, imaging showed several small masses developing next to the BioZorb site. New masses near a previous DCIS treatment bed can raise concern for recurrent disease, even when they appear related to surgery or radiation. Stereotactic biopsy was therefore performed.

The tissue showed fat necrosis, and the pathology was considered consistent with the imaging findings. The masses represented a benign treatment-related change rather than confirmed recurrent DCIS. Her case illustrates how postoperative healing around a BioZorb device can evolve over several years and lead to additional biopsy during routine surveillance.